Clinical Publications

TEMPO

Participant Experience Using Novel Perimetry Tests to Monitor Glaucoma Progression

AUTHORS:

Freeman SE, De Arrigunaga S, Kang J, Zhao Y, Roldán AM, Lin MM, Elze T, Liebman D, Chang DS, Friedman DS.

PUBLICATION:

J Glaucoma. 2023 Nov 1;32(11):948-953. doi: 10.1097/IJG.0000000000002296. Epub 2023 Aug 17.

Study Purpose

To compare patient experience using the IMOvifa SVFA and the tablet-based Melbourne Rapid Fields visual field (VF) tests to the Humphrey Field 24-2 Swedish Interactive Threshold Algorithm Standard

Overview

Study Design

Prospective observational cohort study. Participants completed VFs on the three devices on two study visits 10-24 weeks apart and were surveyed at both visits; participants were instructed to perform weekly MRF VF test at home in between the baseline and final study visit.

# of Eyes/
Patients

81 adults with diagnosis of ocular hypertension, glaucoma suspect, or glaucoma

Study Device

IMO Smart Visual Function Analyzer (referred to as IMOvifa SVFA)*
Humphrey® Visual Field (HVF)
Melbourne Rapid Fields (MRF)

Outcome Measures

Patient response to multiple choice questions surveying: overall experience, device preference, and frequency with which patient would be willing to complete at home tests on each device; Mean test duration

Results

At baseline, participants preferred the SVFA (71.7%) and tablet tests (69.2%) over the Humphrey VF and most were willing to perform weekly monitoring at home on the SVFA (69.1%) and tablet (75.4%)
SVFA and MRF VF tests are significantly faster than HVF for glaucoma patients, and mean test duration was shortest on SVFA VF and longest on HFA for the glaucoma suspect group (all P

IMOvifa reduced measurement time by

39%

Conclusions

Glaucoma patients preferred the IMOvifa SVFA and MRF visual field devices over the HVF. Overall participant experience using these devices was positive, supporting the feasibility of home monitoring of VFs from an experience perspective. At-home VF monitoring would allow for more frequent testing which could detect progression sooner and possibly decrease the burden of office visits on patients, clinical staff, and physicians.